36 results on '"Bruin, Gerard"'
Search Results
2. Chapter 34: A Case Study of Bridging from a Lyophilizate Formulation to an Autoinjector for Patient Self-Administration
3. Advantages of a second ventilation circuit when using a double-lumen endotracheal tube
4. In reply: Use of a second ventilatory circuit when using a double-lumen endotracheal tube
5. Secukinumab dosing every 2 weeks demonstrated superior efficacy compared with dosing every 4 weeks in patients with psoriasis weighing 90 kg or more: results of a randomized controlled trial*
6. Absorption, Distribution, Metabolism, and Excretion of Therapeutic Proteins: Current Industry Practices and Future Perspectives
7. Characterizing the pharmacokinetics and biodistribution of therapeutic proteins: an industry white paper
8. Secukinumab demonstrates efficacy, safety, and tolerability upon administration by 2 ml autoinjector in adult patients with plaque psoriasis: 52‐week results from MATURE, a randomized, placebo‐controlled trial
9. Secukinumab for the treatment of psoriasis, psoriatic arthritis, and axial spondyloarthritis: Physical and pharmacological properties underlie the observed clinical efficacy and safety
10. L’administration du sécukinumab par un auto-injecteur de 2 mL démontre une efficacité élevée avec une sécurité et une tolérance comparables chez les patients adultes atteints de psoriasis en plaques : résultats à 16 semaines de l’étude MATURE
11. β-Defensin 2 is a responsive biomarker of IL-17A–driven skin pathology in patients with psoriasis
12. 27599 Secukinumab administration by a 2 mL autoinjector demonstrates high efficacy with comparable safety and tolerability in adult patients with plaque psoriasis: 16-week results from MATURE
13. 25482 Secukinumab efficacy and safety profile in pediatric patients with severe chronic plaque psoriasis up to 1 year
14. 27519 Efficacy, pharmacokinetics, and tolerability of subcutaneous secukinumab injections with 2 mL prefilled syringes (300 mg) in adult subjects with moderate to severe plaque psoriasis
15. Secukinumab rapidly reduces markers of both keratinocyte proliferation and skin integrity in psoriasis: 1264
16. Secukinumab, a novel anti–IL-17A antibody, exhibits low immunogenicity in clinical trials and human in vitro assays: 1320
17. High Efficacy, Safety, and Tolerability of Secukinumab Injection with 2 mL Auto-injector (300 Mg) in Adult Patients with Moderate to Severe Plaque Psoriasis: 52-week Results from MATURE, a Randomised, Placebo-controlled Trial
18. Efficacy, pharmacokinetics, and tolerability of subcutaneous secukinumab injections with 2 mL prefilled syringes (300 mg) in adult subjects with moderate to severe plaque psoriasis
19. Secukinumab administration by a 2 mL autoinjector demonstrates high efficacy with comparable safety and tolerability in adult patients with plaque psoriasis: 16-week results from MATURE
20. Efficacy, tolerability, patient usability, and satisfaction with a 2 mL pre-filled syringe containing secukinumab 300 mg in patients with moderate to severe plaque psoriasis: results from the phase 3 randomized, double-blind, placebo-controlled ALLURE study
21. Efficacy, tolerability, patient usability, and satisfaction with a 2 mL pre-filled syringe containing secukinumab 300 mg in patients with moderate to severe plaque psoriasis: results from the phase 3 randomized, double-blind, placebo-controlled ALLURE study
22. Comparison of pharmacokinetics, safety and tolerability of secukinumab administered subcutaneously using different delivery systems in healthy volunteers and in psoriasis patients
23. Advantages of a second ventilation circuit when using a double-lumen endotracheal tube
24. Lung re-inflation after one-lung ventilation for thoracic surgery: importance of clamping the dependent lung
25. Secukinumab Treatment Does Not Alter the Pharmacokinetics of the Cytochrome P450 3A4 Substrate Midazolam in Patients With Moderate to Severe Psoriasis
26. Secukinumab Immunogenicity over 52 Weeks in Patients with Psoriatic Arthritis and Ankylosing Spondylitis
27. 263 Secukinumab, a fully human anti-interleukin-17A monoclonal antibody, exhibits low immunogenicity in patients with psoriatic arthritis and ankylosing spondylitis during a 52week treatment period
28. Secukinumab Immunogenicity over 52 Weeks in Patients with Psoriatic Arthritis and Ankylosing Spondylitis.
29. Population Pharmacokinetic Modeling of Secukinumab in Patients With Moderate to Severe Psoriasis
30. Interleukin-17A blockade with secukinumab results in decreased neutrophil infiltration in psoriasis: minimally-invasive measurement by tape stripping
31. Secukinumab, a novel anti-IL-17A antibody, exhibits low immunogenicity in clinical trials and human in vitro assays
32. Secukinumab distributes into dermal interstitial fluid of psoriasis patients as demonstrated by open flow microperfusion
33. Secukinumab distributes into dermal interstitial fluid of psoriasis patients as demonstrated by open flow microperfusion.
34. L’administration du sécukinumab par un auto-injecteur de 2mL démontre une efficacité élevée avec une sécurité et une tolérance comparables chez les patients adultes atteints de psoriasis en plaques : résultats à 16 semaines de l’étude MATURE
35. Reply.
36. Reply: To PMID 25141833.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.